Small Cell Lung Cancer Treatment Market Will Escalate to $2.29 Billion at a CAGR of 27.7% by 2024

Small Cell Lung Cancer Treatment Market
The Small Cell Lung Cancer (SCLC) treatment market is estimated to rise dramatically from $198 million in 2014 to $2.29 billion by 2024, representing a high Compound Annual Growth Rate (CAGR) of 27.7%, according to new research report available on Absolute Reports

The Small Cell Lung Cancer Treatment Market is driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents. The market growth is estimated to occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan.

Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Small Cell Lung Cancer Treatment Market ResearchReport at

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor “Yervoy” will be the first immunotherapy to be introduced in the market. This drug is being developed by Bristol-Myers Squibb and will be launched in 2016 across the seven major markets.

The increase in rates of the disease across the five European markets and Japan, at a CAGR of 1.49% over the forecast period is estimated to further bolster the Small Cell Lung Cancer treatment sales. Although, a reduction in cigarette smoking has caused Small Cell Lung Cancer incidence rates to decrease considerably over the last three decades in US and Japan is now following the footsteps of the US. In this way, although the Small Cell Lung Cancer treatment market will thrive in the short term, its impressive growth may not continue beyond this point.

Ask for Discount on Small Cell Lung Cancer Treatment Market Research Report at –

Key Findings

– The greatest driver of growth within the Global Small Cell Lung Cancer market will be the launch and increased use of premium-priced therapies, including anti-PD-1 immunotherapy and targeted agents such as roniciclib and sacituzumab govitecan. It is expected that Yervoy may reach blockbuster status by the end of the forecast period, with global sales of around $1bn.

– Continuous dosing regimens until disease progression and adoption of maintenance setting following induction therapy for first-line patients will contribute to the increased sales of branded drugs.

– Toxicity is likely to remain a major concern as new first-line treatment options are approved considering companies are developing them in combination with platinum-etoposide. Therefore, substantial opportunity remains to develop therapies that have improved safety profiles compared with agents in the current Small Cell Lung Cancer pipeline.

– An increasing emphasis on cost-consciousness is anticipated over the forecast period, which will limit premium pricing opportunities for developers of SCLC pipeline agents. It is expected that this era of austerity and healthcare reform to make it increasingly more difficult for pharmaceutical companies to gain reimbursement approval for their new Small Cell Lung Cancer therapies.

Request sample PDF of this report at

The report will help one to:

-Develop and decide your strategies for in-licensing and out-licensing through a study of pipeline products and technologies, and by identifying the organisations with robust pipelines.

-Develop strategies by understanding the trends influencing the global Small Cell Lung Cancer therapeutics market.

-Drive revenues by analysing the key trends, market segments, innovative products and technologies, and companies that are likely to affect the Small Cell Lung Cancer market in the future.

-Design effective sales and marketing strategies by understanding the competitive scenario and by analysing the performance of various competitors.

-Identify key emerging players with potentially strong portfolios and create effective counter-strategies to gain competitive advantage.

-Organize your sales and marketing efforts by identifying the market categories and areas that present maximum opportunities for investments, consolidations and strategic partnerships.

Related Report – 

Cancer Treatment Drugs Markets In China – 

China’s demand for Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades.


About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


Media Contact
Company Name: Absolute Reports
Contact Person: Mr. Ameya Pingaley
Email: Send Email
Phone: +1 408 520 9750
Country: India